Annotation Detail
Information
- Associated Genes
- CD274
- Associated Variants
-
CD274 EXPRESSION
CD274 EXPRESSION - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Trial NCT00730639 tested monoclonal antibody nivolumab against the PD-1 immune checkpoint receptor in pretreated patients with various cancer types. PD-L1 expression was tested in 42 patients by ICH from tumor FFPE biopsies. (18 melanoma, 10 NSCLC, 7 colorectal cancer, 5 renal cell cancer, 2 prostate cancer). 9 of 25 PD-L1 expressing patients showed objective response, and zero of 17 PD-L1 negative patients showed objective response (p=0.006). Biopsies were optional, and therefore not fully randomized.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1517
- Gene URL
- https://civic.genome.wustl.edu/links/genes/11335
- Variant URL
- https://civic.genome.wustl.edu/links/variants/276
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Nivolumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 22658127
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Nivolumab | Sensitivity | true |